RandyW Posted September 7, 2007 Share Posted September 7, 2007 Moffitt begins drug trial Tampa Bay Business Journal - 10:20 AM EDT Thursday, September 6, 2007 Introgen Therapeutics Inc. and the H. Lee Moffitt Cancer Center & Research Institute said they would begin a Phase 2 study of an investigational immunotherapy product for patients with metastatic small-cell lung cancer. The product, INGN 22, is an immunotherapy using a patient's own cells to stimulate an anti-tumor immune response to fight cancer, according to a release from Introgen (NASDAQ: INGN), an Austin, Texas-based biopharmaceutical company. The National Institutes of Health National Cancer Institute awarded a grant of about $1.3 million to fund the trial, which is expected to enroll as many as 80 patients starting early next year. It will be co-led by Dr. Dmitry Gabrilovich, professor of oncology at Moffitt, and Dr. Scott Antonia, program leader for immunology and medical director for cellular therapies core. Moffitt Cancer Center in Tampa is the only Florida-based cancer center designated as a comprehensive cancer center by the National Cancer Institute. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.